According to a news source, Co-Diagnostics has entered a joint venture with DNA Logix to bring genetic-testing products and services to highburden developing countries (HBDCs) as part of an effort to address the diagnostic problems associated with infectious diseases unique to those countries. The joint venture, named Co-Diagnostics HBDC, will be based on polymerase chain reaction testing developed by DNA Logix and licensed to the joint venture specifically for sale in HBDCs. DNA Logix CEO Brent Satterfield said about the agreement, “There is a lot of unmet need in the world, and we believe that innovative testing technologies, combined with forward-thinking business models will allow us to reach a much larger number of people.” Both companies are based in Utah. See Genetic Engineering & Biotechnology News and GenomeWeb, July 24, 2013.